000-2019)

Early,
mid-term:
$1 year and
late: >5 years,
reduction in
pain; reduction
in edema;
improvement
in functional
capacity;
VCSS,
Aberdeen,
improvement
in QoL;
avoidance of
initial
venous skin ulceration and
recurrent
ulceration;
improvement
in wound
healing; and
avoidance of
repeat interventions